DNLI - GLP-1s benefit Parkinson's: Barclays sees implications across biopharma
2024-04-12 12:02:53 ET
More on AbbVie, Biogen, etc.
- AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67%
- Novo Nordisk: The Moat Won't Last Forever
- AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision
- No link between weight loss drugs and suicidal thoughts, EU regulator concludes
- Roche, Eli Lilly gain FDA breakthrough device tag for Alzheimer's blood test